HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: J&J Supreme Court Petition, Ostroff Talks Supplement Regulation

This article was originally published in The Tan Sheet

Executive Summary

Supreme Court denies J&J petition in Motrin litigation; FDA chews on latest spiked supplement finding; Ostroff touts supplement market regulation; and more news in brief.

You may also be interested in...



CRN Promotes Counsel, Marketing And Regulatory Directors, Adds Legal, Communications Staff

Megan Olsen moves up to general counsel/senior VP, Gretchen Powers to marketing/member experience VP, Haiuyen Nguyen to regulatory/nutrition policy VP and Tammie Betway to office director/executive assistant to president/CEO. CRN also adds Daniel Garza as legislative/legal assistant and Elise Hall as communications assistant.

J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation

Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.

Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program

Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel